Pharmaceuticals News and Research

RSS

Researchers develop potentially safer and more cost-effective therapeutics against West Nile virus

An international research group led by Arizona State University professor Qiang "Shawn" Chen has developed a new generation of potentially safer and more cost-effective therapeutics against West Nile virus and other pathogens.

29 Mar 2014

Idera Pharmaceuticals reports positive top-line results from Phase 2 trial of IMO-8400

Idera Pharmaceuticals, Inc. today announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis.

28 Mar 2014

ADMA Biologics reports consolidated net loss of $15.5M in 2013

ADMA Biologics, Inc., a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its financial results for the year ended December 31, 2013 and provided recent company developments as well as anticipated milestones for 2014.

28 Mar 2014

Study: Just 1 in 5 eligible for premium subsidies seek coverage

Sign-up rates varied greatly by state, with more than half of the $10 billion allotted so far going to consumers in California, Florida, North Carolina, Texas and New York, according to the Kaiser Family Foundation study. Meanwhile, the Treasury Department allows battered spouses filing separate income taxes to claim subsidies. Also, Merck and GlaxoSmithKline hold off on helping Obamacare enrollees with copays.

28 Mar 2014

Takeda to present results from global EXAMINE CV safety outcomes trial at ACC 2014

Takeda Pharmaceuticals Company Limited will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) safety outcomes trial in a poster session at the American College of Cardiology’s 63rd Annual Scientific Session in Washington, DC.

28 Mar 2014

New policy report on multi-drug resistant tuberculosis

Leading politicians, officials, researchers and civil society organisations convened in Brussels at the launch of European Voice’s multi-drug resistant (MDR-TB) policy report in the lead up to World TB day, to discuss the rising incidence of MDR-TB, the need for more effective treatments, new vaccines and better diagnostics and what needs to done at a European level to tackle this preventable disease.

28 Mar 2014

IRB researchers identify dual role of p38 protein in colon cancer

A team headed by Angel R. Nebreda at the Institute for Research in Biomedicine identifies a dual role of the p38 protein in colon cancer. The study demonstrates that, on the one hand, p38 is important for the optimal maintenance of the epithelial barrier that protects the intestine against toxic agents, thus contributing to decreased tumour development.

28 Mar 2014

Retrophin acquires Manchester Pharmaceuticals

Retrophin, Inc. today announced the completion of the previously announced acquisition of Manchester Pharmaceuticals LLC for a total of $62.5 million, including an upfront payment of $29.5 million, plus other payments based on product sales.

27 Mar 2014

Cytrx releases statement in response to two recent lawsuits

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today issued the following statement in response to two recent lawsuits filed in the name of CytRx shareholders:

27 Mar 2014

SAGE Therapeutics doses first patient in SAGE-547 Phase 1/2 trial for treatment of SRSE

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening and rare central nervous system (CNS) disorders, today announced dose initiation of the first patient in a Phase 1/2 clinical trial of SAGE-547, a neuroactive steroid, in super-refractory status epilepticus (SRSE), a critical condition in which the brain is in a state of persistent seizure.

27 Mar 2014

Alimera Sciences resubmits New Drug Application for ILUVIEN

Alimera Sciences, Inc. (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for ILUVIEN® to the U.S. Food and Drug Administration (FDA).

27 Mar 2014

First Edition: March 27, 2014

Today's headlines include more coverage of the emerging details of the Obama administration's decision to allow some consumers to enroll in health coverage after the March 31 deadline.

27 Mar 2014

ChromaDex declares full-year 2013 financial results

ChromaDex® Corp., an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the financial results for the year ended December 28, 2013.

27 Mar 2014

2014 Biotech China to be held on 14-16 May in Nanjing, China

Biotech China, the first major Chinese biotech exhibition and conference, will hold the 2014 Biotech China on 14-16th May, 2014 in Nanjing, China.

27 Mar 2014

Small-fruited capsicum contains high concentrations of capsinoids

Researchers have released a new Capsicum annuum pepper germplasm that contains high concentrations of capsinoids.

27 Mar 2014

Genetic testing could help determine drug dosage, reduce side effects

Usually pharmaceutical companies determine the drug dosage just as a mean value. This amount may be too much for patients who absorb the substance faster, and too little for those with a slower metabolism.

27 Mar 2014

SLU researchers receive $1.4M grant to study alpha-1 antitrypsin deficiency in adults

Researchers at Saint Louis University will study alpha-1 antitrypsin deficiency in adults, an inherited disease that can cause liver damage, to answer various questions that could lead to effective methods of treatment.

27 Mar 2014

Surveys show drug safety budgets grew between 2012 and 2013, estimated to increase in 2014

Recent surveys by Cutting Edge Information found that the majority of drug safety budgets grew between 2012 and 2013, and are projected to continue growth for 2014.

26 Mar 2014

FMCNA introduces newly branded Frenova Renal Research business

Fresenius Medical Care North America, the world's largest provider of dialysis services, today introduced its newly branded Frenova Renal Research business, the only Phase I-IV drug and device clinical development partner dedicated exclusively to renal research.

26 Mar 2014